vancocin 250 mg kapsler, hårde
strides pharma (cyprus) limited - vancomycinhydrochlorid - kapsler, hårde - 250 mg
vancomycin "fresenius kabi" 1000 mg pulver til koncentrat til infusionsvæske, opløsning
fresenius kabi ab - vancomycinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 1000 mg
vancomycin "mylan" 500 mg pulver til koncentrat til infusionsvæske, opløsning
mylan ireland limited - vancomycinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 500 mg
vancomycin "orion" 1000 mg pulver til koncentrat til infusionsvæske, opløsning
orion corporation - vancomycinhydrochlorid - pulver til koncentrat til infusionsvæske, opløsning - 1000 mg
vancomycin "reig jofre" 500 mg pulver til koncentrat til infusionsvæske, opløsning
laboratorio reig jofre s.a. - vancomycin - pulver til koncentrat til infusionsvæske, opløsning - 500 mg
vancomycin "strides" 125 mg kapsler, hårde
strides pharma (cyprus) limited - vancomycinhydrochlorid - kapsler, hårde - 125 mg
vancomycin "xellia" 250 mg kapsler, hårde
xellia pharmaceuticals aps - vancomycinhydrochlorid - kapsler, hårde - 250 mg
vancomycin "xellia" 500 mg pulver til infusionsvæske, opløsning
xellia pharmaceuticals aps - vancomycinhydrochlorid - pulver til infusionsvæske, opløsning - 500 mg
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant influenzavirus (levende svækket) af følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influenza, human - vacciner - profylakse af influenza i en officielt erklæret pandemisk situation hos børn og unge fra 12 måneder til under 18 år. pandemic influenza vaccine h5n1 astrazeneca bør anvendes i overensstemmelse med officielle retningslinjer.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.